ADMA Biologics Inc.

# Signal Note: Perceptive Advisors Initiates $16.1M Position in ADMA Biologics Edelman's entry into ADMA suggests conviction in the company's commercial execution of neonatal herpes simplex virus (HSV) immunoglobulin (Neoprofin/BIG-IV) and potential label expansions in immunocompromised populations, where unmet need remains substantial. The timing aligns with ongoing commercialization efforts post-FDA approval (2015) and potential pediatric exclusivity data readouts. Given Perceptive's track record backing clinical-stage assets, this signals confidence in ADMA's pipeline depth beyond current revenue generation.